Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
REGULATORY
Gist of FY2022 Drug Pricing Reform
The Central Social Insurance Medical Council (Chuikyo) on December 22 approved an outline of the FY2022 drug pricing reform. The following are key points of the reform package, which will be implemented in April next year. I. Evaluation of Innovation…
To read the full story
Related Article
- Chuikyo OKs FY2022 Drug Pricing Reform Outline; Spillover Exclusion, Mega Seller Rule
December 23, 2021
- Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
- Chuikyo OKs Outline of FY2021 Off-Year Re-Pricing; Only Market Price-Linked Rules to Be Applied
December 21, 2020
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
- Outline of Drug Pricing Reform Package
December 21, 2017
- Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
REGULATORY
- Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
- Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
- Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
- Japan Set to Distribute Pfizer’s COVID Jab for 6 Months to 4 Years of Age from Late October
September 30, 2022
- 2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…